Skip to main content

Table 1 Characteristics of the included studies for osteoarthritis of knee and/or hip

From: Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials

Study, year Treatment (daily dose) Participants randomized (n) Treatment duration (weeks) Symptom duration (year) Mean age (year) Female (%) OA grade Joint Pain outcome extracted Timepoint extracted (weeks)
Glucosamine vs placebo
 Noack 1994 [21] G(1500 mg)/placebo 126/126 1–4 2.00–10.00 55.00 60 I–III Knee Lequesne global scale 4
 Houpt 1999 [22] G(1500 mg)/placebo 58/60 1–8 8.30 64.46 62 NA Knee WOMAC 12
 Reginster 2001 [23] G(1500 mg)/placebo 106/106 1–144 7.80 65.75 76 II–III Knee WOMAC 144
 Pavelka 2002 [24] G(1500 mg)/placebo 101/101 1–144 10.55 62.35 79 II–III Knee WOMAC 144
 Braham 2003 [25] G(1500 mg)/placebo 24/22 1–12 12.98 42.65 28 I–III Knee KPS 12
 McAlinton 2004 [26] G(1500 mg)/placebo 101/104 1–12 NA > 65.00 64 NA Knee WOMAC 12
 Cibere 2004 [27] G(1500 mg)/placebo 71/66 1–24 1.60 64.48 56 ≥ 2 Knee WOMAC 24
 Usha 2004 [28] G(1500 mg)/placebo 30/28 1–12 3.05 51.03 NA I–III Knee VAS 12
 Clegg 2006 [29] G(1500 mg)/placebo 317/313 1–24 9.95 58.40 63 II–III Knee WOMAC 24
 Herrero-Beaumont 2007 [30] G(1500 mg)/placebo 106/104 1–12 7.30 63.94 93 II–III Knee WOMAC 24
 Rozendaal 2008 [31] G(1500 mg)/placebo 111/111 1–12 11.70 63.40 69 > 2 Hip WOMAC 96
 Giordano 2009 [32] G(1500 mg)/placebo 30/30 1–12 6.30 57.65 70 I–III Knee WOMAC 24
 Fransen 2014 [33] G(1500 mg)/placebo 152/151 1–48 > 2.00 60.90 83 NA Knee WOMAC 96
 Kwoh 2014 [34] G(1501 mg)/placebo 98/103 1–12 NA 52.23 49 0–4 Knee WOMAC 24
Chondroitin vs Placebo
 Bucsi 1998 [35] C(1200 mg)/placebo 39/46 1–12 > 0.50 59.95 60 I–III Knee VAS 24
 Bourgeois 1998 [36] C(1200 mg)/placebo 83/44 1–13 NA 63.35 76 I–III Knee VAS 13
 Uebelhart 1998 [37] C(1200 mg)/placebo 23/23 1–48 NA 58.50 52 I–III Knee VAS 48
 Mazieres 2001 [38] C(1200 mg)/placebo 63/67 1–12 NA 67.09 75 II–III Knee Pain at rest 12
 Uebelhart 2004 [39] C(1200 mg)/placebo 54/56 1–12 NA 63.45 81 I–III Knee Husskisson visual analogue score for pain 12
 Michel 2005 [40] C(1200 mg)/placebo 150/150 1–96 NA 62.80 51 I–III Knee WOMAC 96
 Clegg 2006 [29] C(1200 mg)/placebo 318/313 1–24 9.60 58.20 64 II–III Knee WOMAC 24
 Mazieres 2006 [41] C(1200 mg)/placebo 153/154 1–24 6.40 66.00 70 II–III Knee Pain at rest 24
 Kahan 2009 [42] C(1200 mg)/placebo 309/313 1–12 6.30 62.30 68 I–III Knee/hip WOMAC 12
 Wildi 2011 [43] C(800 mg)/placebo 35/34 1–48 > 0.50 62.26 59 I–III Knee WOMAC 48
 Zegels 2013 [7] C(1200 mg)/placebo 236/117 1–12 NA 65.17 65 NA Knee Global pain 12
 Fransen 2014 [33] C(800 mg)/placebo 151/151 1–48 > 2.00 60.05 83 NA Knee WOMAC 96
Glucosamine + Chondroitin vs Placebo
 Clegg 2006 [29] G + C(1500 + 1200 mg)/placebo 317/313 1–24 9.80 58.40 63 II–III Knee WOMAC 24
 Fransen 2014 [33] G + C(1500 + 800 mg)/placebo 151/151 1–48 > 2.00 60.65 85 NA Knee WOMAC 96
 Lugo 2016 [44] G + C(1500 + 1200 mg)/placebo 65/58 1–12 NA 52.84 54 II–III Knee WOMAC 24
 Roman-Blas 2017 [11] G + C(1500 + 1200 mg)/placebo 80/78 1–24 6.20 65.99 84 II–III Knee Global pain 24
  1. G glucosamine, C chondroitin, G + C glucosamine + chondroitin, NA not available, WOMAC Western Ontario and McMaster Universities, KPS Knee Pain Scale, VAS Visual Analogue Scale